<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473938</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-IK-Intragastric-Balloon</org_study_id>
    <nct_id>NCT03473938</nct_id>
  </id_info>
  <brief_title>Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons</brief_title>
  <official_title>Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clínica Opcíon Médica Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Optimal Clinic Tel Aviv</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Faculty, University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intragastric balloon degree of efficacy and duration of effect can be variable and
      unpredictable. The Spatz Adjustable intragastric balloon (AIGB) was developed to extend
      implantation to 1 year, decrease balloon volume for intolerance and increase volume for
      diminishing effect. The aim of the study was to determine the utility/efficacy and responder
      rate with the Spatz3 AIGB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of the Spatz adjustable balloon system have been reported in four studies with
      weight losses of 24.4 kg (48.8% excess weight loss - EWL), 21.6 kg (45.7% EWL),17.2 kg (42.9%
      EWL) and 16.3 kg (67.4% EWL), respectively. The responder rate (&gt;25% EWL) was 88.5% in one
      recent study.

      The authors report and analyze the results of 227 Spatz3 patients retrospectively reviewed in
      3 centers- some adjusted and some not adjusted during the course of their 1-year implantation
      - to determine if the adjustment option can improve overall results and diminish the
      non-responder rate.

      The Spatz3 Adjustable intragastric balloon (IGB) (Spatz FGIA, Inc. New York, USA) was
      implanted at the following centers between May and December 2015: University Hospital,
      Ostrava, Czech Republic, Clinica Opcion Medica, Barcelona, Spain, and Optimal Clinic, Tel
      Aviv, Israel. Patients were selected according to the well-established criteria for
      intragastric balloon implantation, consistent with NIH and CE Mark guidelines, and were
      independently evaluated by members of the staff: gastroenterologists, dieticians, and
      psychologists. Indications for Spatz3 Adjustable IGB implantation included one of the
      following: (1) temporary weight loss treatment in a patient with body mass index (BMI) in the
      range of bariatric surgery (&gt;35) who refuse surgery or are at high risk for surgery, (2)
      temporary weight loss treatment for a patient without indications for surgery (BMI&gt;29). All
      patients underwent upper gastrointestinal endoscopy using conscious sedation with or without
      an anesthetist using one or more of the following medications - Propofol, Midazolam, and
      Fentanyl.

      Balloons were inflated with a mean 464ml (400-500ml) of normal saline with the addition of
      2-3 ml of a 1% solution of Methylene Blue (not used in the Czech Republic center). Patients
      were recovered for 45 minutes and discharged the same day on a once-daily PPI, anti-nausea
      medications (Aprepitant 125 mg day 1; 80 mg days 2 and 3), ondansetron (8 mg Q6H X 3 days),
      anti-spasmodic (papaverine 80 mg tid prn), and dietary instructions. After the fifth
      post-procedure day, a progressive full liquid to soft to solid 1,200-1,400 kcal diet was
      started. Monthly follow up with dietician and/or doctor (gastroenterologist or
      endocrinologist) was offered to all patients after implantation. Cognitive behavioral therapy
      by licensed psychologists was offered in 2 of the 3 centers (206/227 patients) with 6-10
      sessions after implantation. Patients who were intolerant to the balloon could be adjusted
      downward by 100-150 ml. Patients with one or more of the following were offered upward
      adjustments of the balloon volume (200-400 ml at the discretion of the endoscopist): weight
      loss plateau; lack of balloon effect; ability to overeat without resultant symptoms (any of
      the following: nausea, vomiting, bloating, eructation, abdominal pain, acid reflux symptoms).
      Preparation for an adjustment or extraction procedure required the following diet: 3 days
      prior- no meat or vegetables; 2 days prior- full liquids; 1 day prior- clear liquids and NPO
      after midnight. After 12 months of placement, the balloon was deflated by aspiration via
      standard balloon needle or deflation utilizing the valve, and extraction was completed using
      a grasping forceps or a polypectomy snare - all under conscious sedation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>8 months</time_frame>
    <description>The achieved weight loss was recorded for the patients in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Balloon intolerance</measure>
    <time_frame>8 months</time_frame>
    <description>Intolerance of the intragastric balloon was recorded.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">227</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Spatz3 AIGB</arm_group_label>
    <description>Patients with implanted Spatz3 AIGB balloon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spatz3 AIGB</intervention_name>
    <description>Implantation of Spatz3 AIGB balloon.</description>
    <arm_group_label>Spatz3 AIGB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a temporary weight loss treatment, with body mass index (BMI) in the range of
        bariatric surgery (&gt;35) who refuse surgery or are at high risk for surgery or a temporary
        weight loss treatment without indications for surgery (BMI &gt; 29).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  temporary weight loss treatment in a patient with body mass index (BMI) in the range
             of bariatric surgery (&gt;35) who refuse surgery or are at high risk for surgery

          -  temporary weight loss treatment for a patient without indications for surgery (BMI &gt;
             29)

        Exclusion Criteria:

        - none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Evžen Machytka, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>701 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Clinic</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Opcíon Médica</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40-4. doi: 10.1159/000109385. Epub 2008 Feb 15. Review.</citation>
    <PMID>18600014</PMID>
  </reference>
  <reference>
    <citation>Imaz I, Martínez-Cervell C, García-Alvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008 Jul;18(7):841-6. doi: 10.1007/s11695-007-9331-8. Epub 2008 May 6. Review.</citation>
    <PMID>18459025</PMID>
  </reference>
  <reference>
    <citation>Bonazzi P, Petrelli MD, Lorenzini I, Peruzzi E, Nicolai A, Galeazzi R. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5 Suppl 1):15-21.</citation>
    <PMID>16457125</PMID>
  </reference>
  <reference>
    <citation>Mion F, Napoléon B, Roman S, Malvoisin E, Trepo F, Pujol B, Lefort C, Bory RM. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005 Apr;15(4):510-6.</citation>
    <PMID>15946431</PMID>
  </reference>
  <reference>
    <citation>Evans JD, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001 Sep;88(9):1245-8.</citation>
    <PMID>11531875</PMID>
  </reference>
  <reference>
    <citation>Sallet JA, Marchesini JB, Paiva DS, Komoto K, Pizani CE, Ribeiro ML, Miguel P, Ferraz AM, Sallet PC. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004 Aug;14(7):991-8.</citation>
    <PMID>15329191</PMID>
  </reference>
  <reference>
    <citation>Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, Docimo C, Lorenzo M, Basso N. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006 Jan;30(1):129-33.</citation>
    <PMID>16189503</PMID>
  </reference>
  <reference>
    <citation>Doldi SB, Micheletto G, Perrini MN, Rapetti R. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004 Jan-Feb;51(55):294-7. Retraction in: Hepatogastroenterology. 2012 Nov-Dec;59(120):2683.</citation>
    <PMID>15025034</PMID>
  </reference>
  <reference>
    <citation>Roman S, Napoléon B, Mion F, Bory RM, Guyot P, D'Orazio H, Benchetrit S. Intragastric balloon for &quot;non-morbid&quot; obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004 Apr;14(4):539-44.</citation>
    <PMID>15130235</PMID>
  </reference>
  <reference>
    <citation>Doldi SB, Micheletto G, Di Prisco F, Zappa MA, Lattuada E, Reitano M. Intragastric balloon in obese patients. Obes Surg. 2000 Dec;10(6):578-81.</citation>
    <PMID>11175969</PMID>
  </reference>
  <reference>
    <citation>Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005 Jan;15(1):101-5.</citation>
    <PMID>15760507</PMID>
  </reference>
  <reference>
    <citation>Herve J, Wahlen CH, Schaeken A, Dallemagne B, Dewandre JM, Markiewicz S, Monami B, Weerts J, Jehaes C. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005 Jun-Jul;15(6):864-70.</citation>
    <PMID>15978160</PMID>
  </reference>
  <reference>
    <citation>Melissas J, Mouzas J, Filis D, Daskalakis M, Matrella E, Papadakis JA, Sevrisarianos N, Charalambides D. The intragastric balloon - smoothing the path to bariatric surgery. Obes Surg. 2006 Jul;16(7):897-902.</citation>
    <PMID>16839490</PMID>
  </reference>
  <reference>
    <citation>Busetto L, Segato G, De Luca M, Bortolozzi E, MacCari T, Magon A, Inelmen EM, Favretti F, Enzi G. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg. 2004 May;14(5):671-6.</citation>
    <PMID>15186637</PMID>
  </reference>
  <reference>
    <citation>Doldi SB, Micheletto G, Perrini MN, Librenti MC, Rella S. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002 Aug;12(4):583-7.</citation>
    <PMID>12194556</PMID>
  </reference>
  <reference>
    <citation>Totté E, Hendrickx L, Pauwels M, Van Hee R. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001 Aug;11(4):519-23.</citation>
    <PMID>11501367</PMID>
  </reference>
  <reference>
    <citation>Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, Shayani V, Billy H, Pambianco D, Gostout C. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017 Mar;41(3):427-433. doi: 10.1038/ijo.2016.229. Epub 2016 Dec 23.</citation>
    <PMID>28017964</PMID>
  </reference>
  <reference>
    <citation>Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, Lopez-Nava G, Shikora S, Brooks J. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011 Oct;21(10):1499-507. doi: 10.1007/s11695-011-0424-z.</citation>
    <PMID>21553304</PMID>
  </reference>
  <reference>
    <citation>Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014 May;24(5):813-9. doi: 10.1007/s11695-014-1176-3.</citation>
    <PMID>24442419</PMID>
  </reference>
  <reference>
    <citation>Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity (Silver Spring). 2016 Sep;24(9):1849-53. doi: 10.1002/oby.21555. Epub 2016 Jul 28.</citation>
    <PMID>27465076</PMID>
  </reference>
  <reference>
    <citation>Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005 Jan;61(1):19-27.</citation>
    <PMID>15672051</PMID>
  </reference>
  <reference>
    <citation>Dastis NS, François E, Deviere J, Hittelet A, Ilah Mehdi A, Barea M, Dumonceau JM. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009 Jul;41(7):575-80. doi: 10.1055/s-0029-1214826. Epub 2009 Jul 8.</citation>
    <PMID>19588283</PMID>
  </reference>
  <reference>
    <citation>Al Kahtani K, Khan MQ, Helmy A, Al Ashgar H, Rezeig M, Al Quaiz M, Kagevi I, Al Sofayan M, Al Fadda M. Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal Specialist Hospital experience. Obes Surg. 2010 Sep;20(9):1219-26. doi: 10.1007/s11695-008-9654-0. Epub 2008 Aug 28.</citation>
    <PMID>18752030</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Intragastric balloons</keyword>
  <keyword>Adjustable gastric balloon</keyword>
  <keyword>Weight loss plateau</keyword>
  <keyword>Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The authors have no plan make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

